A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Treatment Resistant Depression
Interventions
DRUG

PCN-101

Concentrate for solution for infusion

DRUG

Placebo

Concentrate for solution for infusion

Trial Locations (21)

19053

Somni bene GmbH, Schwerin

30060

Psych Atlanta, Marietta

33122

Premier Clinical Research Institute Inc., Miami

44720

Neuro-Behavioral Clinical Research, North Canton

45417

Midwest Clinical Research Center, Dayton

60528

Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt

72211

Preferred Research Partners, Little Rock

75080

Pillar Clinical Research, LLC, Richardson

75115

Insite Clinical Research LLC; Inpatient facility name: Serenity, DeSoto

91945

Synergy San Diego, Lemon Grove

92037

Kadima Neuropsychiatry Institute, La Jolla

92845

CNS Network, Garden Grove

92868

NRC Research Institute, Orange

97080

Universitaetsklinikum Wuerzburg, Würzburg

08009

Hassman Research Institute, Berlin

08540

Princeton Medical Institute, Princeton

09648

Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida

80-438

Indywidualna Specjalistyczna Praktyka Lekarska, Gdansk

80-546

Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk

86-100

Wojewodzki Szpital Dla Nerwowo i Psychicznie Chorych, Gmina Świecie

95-080

Prywatny Gabinet Lekarski Jaroslaw Strzelec, Tuszyn

All Listed Sponsors
collaborator

Precision For Medicine

INDUSTRY

collaborator

IQVIA Biotech

INDUSTRY

lead

Perception Neuroscience

INDUSTRY

NCT05414422 - A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD | Biotech Hunter | Biotech Hunter